Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Functional analysis of the C. elegans cyld-1 gene reveals extensive similarity with its human homolog.

Hadweh P, Chaitoglou I, Gravato-Nobre MJ, Ligoxygakis P, Mosialos G, Hatzivassiliou E.

PLoS One. 2018 Feb 2;13(2):e0191864. doi: 10.1371/journal.pone.0191864. eCollection 2018.

2.

Down-regulation of the Tumor Suppressor CYLD Enhances the Transformed Phenotype of Human Breast Cancer Cells.

Orfanidou T, Xanthopoulos K, Dafou D, Pseftogas A, Hadweh P, Psyllaki C, Hatzivassiliou E, Mosialos G.

Anticancer Res. 2017 Jul;37(7):3493-3503.

PMID:
28668838
3.

Activation of peroxisome proliferator-activated receptor gamma in mammary epithelial cells upregulates the expression of tumor suppressor Cyld to mediate growth inhibition and anti-inflammatory effects.

Pseftogas A, Gonidas C, Mosialos G.

Int J Biochem Cell Biol. 2017 Jan;82:49-56. doi: 10.1016/j.biocel.2016.11.011. Epub 2016 Nov 16.

PMID:
27865894
4.

The expression of tumor suppressor gene Cyld is upregulated by histone deacetylace inhibitors in human hepatocellular carcinoma cell lines.

Kotantaki P, Mosialos G.

Cell Biochem Funct. 2016 Oct;34(7):465-468. doi: 10.1002/cbf.3212. Epub 2016 Aug 29.

PMID:
27570065
5.

Epidermal CYLD inactivation sensitizes mice to the development of sebaceous and basaloid skin tumors.

Jin YJ, Wang S, Cho J, Selim MA, Wright T, Mosialos G, Zhang JY.

JCI Insight. 2016 Jul 21;1(11). pii: e86548.

6.

Inactivation of CYLD in intestinal epithelial cells exacerbates colitis-associated colorectal carcinogenesis - a short report.

Karatzas DN, Xanthopoulos K, Kotantaki P, Pseftogas A, Teliousis K, Hatzivassiliou EG, Kontoyiannis DL, Poutahidis T, Mosialos G.

Cell Oncol (Dordr). 2016 Jun;39(3):287-93. doi: 10.1007/s13402-016-0279-3. Epub 2016 Apr 4.

PMID:
27042826
7.

The PP4R1 subunit of protein phosphatase PP4 targets TRAF2 and TRAF6 to mediate inhibition of NF-κB activation.

Hadweh P, Habelhah H, Kieff E, Mosialos G, Hatzivassiliou E.

Cell Signal. 2014 Dec;26(12):2730-7. doi: 10.1016/j.cellsig.2014.08.001. Epub 2014 Aug 16.

PMID:
25134449
8.

Identification of protein kinase inhibitors with a selective negative effect on the viability of Epstein-Barr virus infected B cell lines.

Mavromatidis V, Varga Z, Waczek F, Őrfi Z, Őrfi L, Kéri G, Mosialos G.

PLoS One. 2014 Apr 23;9(4):e95688. doi: 10.1371/journal.pone.0095688. eCollection 2014.

9.

Protein kinase N1, a cell inhibitor of Akt kinase, has a central role in quality control of germinal center formation.

Yasui T, Sakakibara-Yada K, Nishimura T, Morita K, Tada S, Mosialos G, Kieff E, Kikutani H.

Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):21022-7. doi: 10.1073/pnas.1218925110. Epub 2012 Dec 5.

10.

Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer.

Nikolaou K, Tsagaratou A, Eftychi C, Kollias G, Mosialos G, Talianidis I.

Cancer Cell. 2012 Jun 12;21(6):738-50. doi: 10.1016/j.ccr.2012.04.026.

11.

Genomic analysis reveals a novel nuclear factor-κB (NF-κB)-binding site in Alu-repetitive elements.

Antonaki A, Demetriades C, Polyzos A, Banos A, Vatsellas G, Lavigne MD, Apostolou E, Mantouvalou E, Papadopoulou D, Mosialos G, Thanos D.

J Biol Chem. 2011 Nov 4;286(44):38768-82. doi: 10.1074/jbc.M111.234161. Epub 2011 Sep 5.

12.

Differential requirement of IKK2 for CYLD-dependent representation of thymic and peripheral T-cell populations.

Tsagaratou A, Grammenoudi S, Mosialos G.

Eur J Immunol. 2011 Oct;41(10):3054-62. doi: 10.1002/eji.201041160. Epub 2011 Aug 30.

13.

Truncation of the deubiquitinating domain of CYLD in myelomonocytic cells attenuates inflammatory responses.

Tsagaratou A, Kontoyiannis DL, Mosialos G.

PLoS One. 2011 Jan 20;6(1):e16397. doi: 10.1371/journal.pone.0016397.

14.

Mutational analysis of TRAF6 reveals a conserved functional role of the RING dimerization interface and a potentially necessary but insufficient role of RING-dependent TRAF6 polyubiquitination towards NF-κB activation.

Megas C, Hatzivassiliou EG, Yin Q, Marinopoulou E, Hadweh P, Vignali DA, Mosialos G.

Cell Signal. 2011 May;23(5):772-7. doi: 10.1016/j.cellsig.2010.12.004. Epub 2010 Dec 23.

15.

Glutaredoxin-1 regulates TRAF6 activation and the IL-1 receptor/TLR4 signalling.

Chantzoura E, Prinarakis E, Panagopoulos D, Mosialos G, Spyrou G.

Biochem Biophys Res Commun. 2010 Dec 17;403(3-4):335-9. doi: 10.1016/j.bbrc.2010.11.029. Epub 2010 Nov 13.

PMID:
21078302
16.

Thymocyte-specific truncation of the deubiquitinating domain of CYLD impairs positive selection in a NF-kappaB essential modulator-dependent manner.

Tsagaratou A, Trompouki E, Grammenoudi S, Kontoyiannis DL, Mosialos G.

J Immunol. 2010 Aug 15;185(4):2032-43. doi: 10.4049/jimmunol.0903919. Epub 2010 Jul 19.

17.

Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation.

Trompouki E, Tsagaratou A, Kosmidis SK, Dollé P, Qian J, Kontoyiannis DL, Cardoso WV, Mosialos G.

Neoplasia. 2009 May;11(5):469-76.

18.

The LMP1 promoter can be transactivated directly by NF-kappaB.

Demetriades C, Mosialos G.

J Virol. 2009 May;83(10):5269-77. doi: 10.1128/JVI.00097-09. Epub 2009 Mar 11.

19.

A Drosophila ortholog of the human cylindromatosis tumor suppressor gene regulates triglyceride content and antibacterial defense.

Tsichritzis T, Gaentzsch PC, Kosmidis S, Brown AE, Skoulakis EM, Ligoxygakis P, Mosialos G.

Development. 2007 Jul;134(14):2605-14. Epub 2007 Jun 6.

20.

Constitutive CD40 signaling phenocopies the transforming function of the Epstein-Barr virus oncoprotein LMP1 in vitro.

Hatzivassiliou EG, Kieff E, Mosialos G.

Leuk Res. 2007 Mar;31(3):315-20. Epub 2006 Aug 17.

PMID:
16919331
21.

Human ubiquitin specific protease 31 is a deubiquitinating enzyme implicated in activation of nuclear factor-kappaB.

Tzimas C, Michailidou G, Arsenakis M, Kieff E, Mosialos G, Hatzivassiliou EG.

Cell Signal. 2006 Jan;18(1):83-92. Epub 2005 Apr 26.

PMID:
16214042
22.

The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene.

Wang L, Baiocchi RA, Pal S, Mosialos G, Caligiuri M, Sif S.

Mol Cell Biol. 2005 Sep;25(18):7953-65.

23.
24.

Comparative analysis of signal transduction by CD40 and the Epstein-Barr virus oncoprotein LMP1 in vivo.

Panagopoulos D, Victoratos P, Alexiou M, Kollias G, Mosialos G.

J Virol. 2004 Dec;78(23):13253-61.

25.

NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway.

Jono H, Lim JH, Chen LF, Xu H, Trompouki E, Pan ZK, Mosialos G, Li JD.

J Biol Chem. 2004 Aug 27;279(35):36171-4. Epub 2004 Jun 28.

26.

Epstein-Barr virus latent membrane protein 1 activation of NF-kappaB through IRAK1 and TRAF6.

Luftig M, Prinarakis E, Yasui T, Tsichritzis T, Cahir-McFarland E, Inoue J, Nakano H, Mak TW, Yeh WC, Li X, Akira S, Suzuki N, Suzuki S, Mosialos G, Kieff E.

Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15595-600. Epub 2003 Dec 12.

27.

CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members.

Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G.

Nature. 2003 Aug 14;424(6950):793-6.

28.
29.

Cellular signaling pathways engaged by the Epstein-Barr virus transforming protein LMP1.

Hatzivassiliou E, Mosialos G.

Front Biosci. 2002 Jan 1;7:d319-29. Review.

PMID:
11779697
30.

Cytokine signaling and Epstein-Barr virus-mediated cell transformation.

Mosialos G.

Cytokine Growth Factor Rev. 2001 Jun-Sep;12(2-3):259-70. Review.

PMID:
11325606
32.

Effects of the NIK aly mutation on NF-kappaB activation by the Epstein-Barr virus latent infection membrane protein, lymphotoxin beta receptor, and CD40.

Luftig MA, Cahir-McFarland E, Mosialos G, Kieff E.

J Biol Chem. 2001 May 4;276(18):14602-6. Epub 2001 Mar 14.

33.

The X-linked lymphoproliferative syndrome gene product SH2D1A associates with p62dok (Dok1) and activates NF-kappa B.

Sylla BS, Murphy K, Cahir-McFarland E, Lane WS, Mosialos G, Kieff E.

Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7470-5.

34.

Epstein-barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kappaB.

Cahir McFarland ED, Izumi KM, Mosialos G.

Oncogene. 1999 Nov 22;18(49):6959-64. Review.

35.

Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression.

Devergne O, Cahir McFarland ED, Mosialos G, Izumi KM, Ware CF, Kieff E.

J Virol. 1998 Oct;72(10):7900-8.

36.

Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta.

Sylla BS, Hung SC, Davidson DM, Hatzivassiliou E, Malinin NL, Wallach D, Gilmore TD, Kieff E, Mosialos G.

Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10106-11.

38.
39.
40.

Lymphotoxin-beta receptor signaling complex: role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor kappaB.

VanArsdale TL, VanArsdale SL, Force WR, Walter BN, Mosialos G, Kieff E, Reed JC, Ware CF.

Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2460-5.

41.

Fascin, a sensitive new marker for Reed-Sternberg cells of hodgkin's disease. Evidence for a dendritic or B cell derivation?

Pinkus GS, Pinkus JL, Langhoff E, Matsumura F, Yamashiro S, Mosialos G, Said JW.

Am J Pathol. 1997 Feb;150(2):543-62.

43.

Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation.

Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnen MF, Kieff E, Mosialos G.

Mol Cell Biol. 1996 Dec;16(12):7098-108.

44.

Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation.

Ansieau S, Scheffrahn I, Mosialos G, Brand H, Duyster J, Kaye K, Harada J, Dougall B, Hübinger G, Kieff E, Herrmann F, Leutz A, Gruss HJ.

Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14053-8. Retraction in: Kieff E. Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12732.

45.

CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator.

Eliopoulos AG, Dawson CW, Mosialos G, Floettmann JE, Rowe M, Armitage RJ, Dawson J, Zapata JM, Kerr DJ, Wakelam MJ, Reed JC, Kieff E, Young LS.

Oncogene. 1996 Nov 21;13(10):2243-54.

PMID:
8950992
46.

Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region.

Ishida T, Mizushima Si, Azuma S, Kobayashi N, Tojo T, Suzuki K, Aizawa S, Watanabe T, Mosialos G, Kieff E, Yamamoto T, Inoue J.

J Biol Chem. 1996 Nov 15;271(46):28745-8.

47.

Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein.

Kaye KM, Devergne O, Harada JN, Izumi KM, Yalamanchili R, Kieff E, Mosialos G.

Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11085-90.

48.

Circulating human dendritic cells differentially express high levels of a 55-kd actin-bundling protein.

Mosialos G, Birkenbach M, Ayehunie S, Matsumura F, Pinkus GS, Kieff E, Langhoff E.

Am J Pathol. 1996 Feb;148(2):593-600.

49.
50.

The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family.

Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E.

Cell. 1995 Feb 10;80(3):389-99.

Supplemental Content

Loading ...
Support Center